Overall, these results suggested that aberrant DNA demethylation modifications (ie. p66Shc, Drp1, Ribonuclease 6, IL-6, SLAM7, and lipoprotein-associated phospholipase A2) contribute to atherosclerosis progression and its potential role in atherosclerosis as a therapeutic target. This evidence concerns the gene RNASET2 and atherosclerosis.